Kiadis Pharma Obtains FDA Approval to Start a Phase III Clinical Trial for Reviroc(TM) in the United States
Posted on: Friday, 22 February 2008, 09:00 CST
AMSTERDAM, February 22 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma announced today that the US Food and Drug Administration (FDA) approved Kiadis Pharma's investigational new drug ("IND") application to allow the start of a clinical phase III study for its product Reviroc(TM) in the United States. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.
This approval follows the successful End of Phase II meeting with the FDA for Reviroc(TM) and the subsequent submission of the IND package to the FDA. As part of the End of Phase II meeting the FDA offered its Special Protocol Assessment (SPA) for Reviroc(TM) for protocol design of a phase III clinical study. Kiadis Pharma will initiate the start of a phase III study upon completion of the SPA.
The completed phase II study has shown an effective elimination of cancer cells from the patients autologous bone marrow graft prior to the transplantation and shows an encouraging overall survival after autologous bone marrow transplantations in Non-Hodgkin's lymphoma patients.
"We are very pleased with this IND approval received from the FDA and look forward to completing the SPA as well to allow us to start enrolment of patients in the study," commented Manja Bouman, CEO of Kiadis Pharma.
About Reviroc(TM)
Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft.
About Kiadis Pharma
Kiadis Pharma is a biopharmaceutical company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three blood cancer products in clinical development, offering novel treatment options for terminally ill cancer patients and address high-unmet medical needs.
http://www.kiadis.com/
Kiadis Pharma
CONTACT: Contact: Kiadis Pharma B.V., Eefje Simpelaar, DirectorCommunications, e.simpelaar@kiadis.com, +31-20-8884815
Source: PRNewswire
Related Articles
- Randomized Phase 2 Study of IMC-A12 for Advanced Breast Cancer Commences Patient Enrollment
- Exforge(R) Helps Nearly Twice As Many Patients Control Their High Blood Pressure Compared to Amlodipine Alone
- Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
- NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- Delaware Cancer Patients Among Nation's First to Benefit From Expansion of the American Cancer Society's 'Patient Navigator Program'
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated By NCI CALGB in Patients With Metastatic Colorectal Cancer; First Patients Treated
- Positive Findings From Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients With Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
- Tampa General Hospital Approved to Enroll Patients in Synthetic Blood International's Phase II Oxycyte Trial
 |
 |
User Comments (0)
RSS Feeds